Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors ≤ 2 cm: A meta-analysis of the randomized trastuzumab trials Review uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Breast Neoplasms
  • Receptor, ErbB-2

abstract

  • Women with HER2-positive tumors ≤ 2 cm in the randomized trastuzumab trials derived substantial DFS and OS benefit from adjuvant trastuzumab. Trastuzumab-treated patients with HR-positive disease and ≤ one positive lymph node may be candidates for trials assessing less aggressive treatment approaches.

publication date

  • August 20, 2015

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4534523

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.60.8620

PubMed ID

  • 26101239

Additional Document Info

start page

  • 2600

end page

  • 8

volume

  • 33

number

  • 24